Join us: Tuesday, October 12, 2021 at 3:00pm
The Knight Campus Distinguished Lecture is an annual event designed to bring nationally and internationally recognized science, technology and engineering leaders to the University of Oregon community to give their perspective on the future of their fields.
The next seminar will be on Tuesday, October 12, with Karen Wooley. We hope you can join us!
More event details and registration coming soon!
W.T. Doherty-Welch Chair in Chemistry and Distinguished Professor, Texas A&M University
Karen L. Wooley holds the W.T. Doherty-Welch Chair in Chemistry and is a University Distinguished Professor at Texas A&M University, with appointments in the Departments of Chemistry, Chemical Engineering and Materials Science & Engineering. She completed undergraduate study at Oregon State University (B.S., 1988), graduate study at Cornell University (Ph.D., 1993), and then spent the first sixteen years of her independent academic career on the faculty at Washington University in St. Louis. Nearly twelve years ago, she relocated to Texas A&M University (July 2009).
Karen's research interests include the synthesis and characterization of degradable polymers derived from natural products, unique macromolecular architectures and complex polymer assemblies, and well-defined nanostructured materials, with an emphasis on the design and development of materials that address societal, medical, technological and/or environmental advances. Although 2020 was a challenging year for Karen’s family and many around the world personally due to the COVID-19 pandemic, professionally, her career thrived, with her being awarded Fellowship to the American Association of the Advancement of Science (2020), the American Institute for Medical and Biological Engineering (2020), and the National Academy of Sciences (2020). She has recently been awarded a 2021 Southeastern Conference (SEC) Faculty Achievement Award and has been named the 2021 SEC Professor of the Year.
Director, Knight Cancer Institute
"Imatinib as a Paradigm of Targeted Cancer Therapies"
Brian Druker discussed how he spearheaded the highly successful clinical trials of imatinib for chronic myeloid leukemia, which led to FDA approval of the drug in record time.
CEO and Co-Founder, Chronicle
"Innovation, Leadership, and Change"
Stephen Gillett discussed leadership, transformation, and change and how these elements shaped him into a leader that skirts the norm, strives for innovation, and views change as an opportunity, not a roadblock.